Physician profile
John M Blumer
NPI 1619984150
$4,521.73
in general payments reported to CMS, 2019-2025
48 companies · $705 in 2025
The $705 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $394 · 2021: $607 · 2022: $777 · 2023: $626 · 2024: $774 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.51 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $589.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $371.06 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $298.23 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Abbvie INC. | $289.00 | 2021-2025 | Vraylar |
| Astellas Pharma US INC | $270.27 | 2019-2024 | Veozah, Myrbetriq |
| Sunovion Pharmaceuticals INC. | $240.15 | 2019-2021 | |
| Pfizer INC. | $199.56 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.50 | 2020-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $180.15 | 2019-2025 | General - Pain Management |
| Bayer Healthcare Pharmaceuticals INC. | $168.97 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $142.69 | 2019-2023 | |
| Abbott Laboratories | $134.23 | 2022-2025 | Freestyle Libre, Freestyle Libre 2 |
| Lilly USA, LLC | $130.03 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $102.27 | 2020-2025 | Farxiga, Fasenra, Airsupra |
| Sanofi-Aventis U.S. LLC | $87.83 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Blumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.